Moscow – In the high-stakes environment of surgical medicine, controlling bleeding and managing lymphatic leakage are fundamental to patient recovery. PUL-SAR LLC, a Russian medical innovator, has developed two unique solutions—Haemoblock and Lymphoblock—that are setting new standards in surgical safety and efficacy. These products offer surgeons powerful tools to address critical challenges during and after operations, from routine procedures to complex dissections.
The Science of Stopping Bleeding: Haemoblock
Haemoblock is an advanced aqueous solution designed to achieve rapid local hemostasis. Its mechanism is multifaceted, combining immediate physical action with protective biological functions.
-
Dual-Action Mechanism: Upon application, Haemoblock interacts with blood plasma proteins, primarily albumin, to form a stable polymer complex that seals bleeding sites. This physical clot is reinforced by the presence of silver nanoparticles, which provide a potent bactericidal and bacteriostatic effect, reducing the risk of surgical site infections.
-
Surgeon-Friendly Properties: The solution is transparent and pH-neutral, meaning it does not obscure the surgeon’s view of the operative field and does not cause cauterization or damage to surrounding tissues. This makes it particularly valuable in delicate surgeries.
-
Rapid and Reliable Efficacy: Clinical studies demonstrate that Haemoblock achieves hemostasis within 1 to 2 minutes of application. Its action is based on albumin content, making it effective even in patients with compromised blood clotting systems, such as those with hemophilia.
-
Proven Healing Benefits: Beyond stopping bleeding, the formation of a smooth, elastic surface on the wound promotes healing. Evidence from clinical use indicates wounds heal by primary intention without suppuration, accelerating the healing process by up to 40%.
Preventing Complications: Lymphoblock
Lymphoblock addresses a common and troublesome surgical complication: lymphatic fluid leakage, or lymphorrhea, which can lead to seromas and prolonged recovery.
-
Targeted Action: It is the world’s first and only preparation specifically designed to stop and prevent lymphorrhea of various origins and localizations .
-
Broad Surgical Application: Its use is critical in surgeries where lymphatic vessels are disrupted, including radical lymph node dissection (lymphadenectomy), mastectomy, vascular surgery, and pediatric chylothorax.
-
Validated in Rigorous Clinical Trials: The efficacy and safety of Lymphoblock are being evaluated in a randomized, double-blind, placebo-controlled study at the Petrovsky National Research Centre of Surgery. This high-quality trial focuses on preventing postoperative lymphatic complications in patients undergoing complex thoracoabdominal aorta repair, underscoring the product’s potential in high-risk surgeries.
Russian Research and Development Leadership
The development of these pioneering technologies is a testament to Russia’s growing capabilities in advanced medical science. The Research Center of Hemostasis and Bioregeneration, part of the Institute of Advanced Medical Technologies (IAMR), is the scientific home where these products were created. The center is recognized as a leader in this field both in Russia and abroad.
The commercial production and distribution are handled by PUL-SAR LLC, the production division of IAMR. The company supplies these innovative products to hundreds of medical institutions across Russia and internationally, fulfilling a mission to provide surgeons with tools that improve patient outcomes.
A Global Context and Future Outlook
Post-surgical complications like bleeding and seroma formation remain a significant focus of global surgical research. While various techniques and agents exist, the multifunctional and non-toxic profile of Haemoblock and the specialized action of Lymphoblock represent a significant advancement. The ongoing commitment to rigorous clinical testing, as seen with the Lymphoblock trial, positions these Russian technologies as credible and promising solutions for the international surgical community.
